Pancreatic cancer, malignant (ICD10 C25): combined sexes

One-year relative survival by diagnosis year and age at diagnosis

	One-year relative survival (with 95% confidence interval) by diagnosis year
Age at diagnosis	1994-97	1998-2002	2003-2007	2007-2009	EUROCARE-4	EUROCARE-4
	cohort	cohort	cohort	*hybrid	##1995-1999	##1995-1999

all 15-99	13.2%	14.3%	18.3%	19.0%
(unstandardized)	(11.3-15.2%)	(12.6-16.1%)	(16.5-20.1%)	(16.9-21.2%)

all 15-99	14.1%	16.5%	20.6%	22.4%	14.9%	20.9%
(age-standardized)#	(9.7-19.5%)	(12.1-21.1%)	(16.1-25.2%)	(16.7-28.3%)	(12.9-17.1%)	(20.5-21.4%)

15-44	17.4%	37.6%	42.6%	55.3%
	(5.4-35.0%)	(24.1-50.9%)	(28.3-56.1%)	(35.7-71.1%)

45-54	20.7%	22.4%	30.1%	32.4%
	(13.3-29.2%)	(15.1-30.5%)	(22.7-37.8%)	(22.7-42.3%)

55-64	14.6%	19.5%	23.6%	24.7%
	(10.0-19.9%)	(14.9-24.4%)	(19.3-28.1%)	(19.4-30.2%)

65-74	14.1%	13.6%	17.4%	18.5%
	(10.8-17.7%)	(10.7-16.7%)	(14.1-20.8%)	(14.4-22.8%)

75-99	10.2%	9.4%	12.3%	12.6%
	(7.7-13.1%)	(7.3-11.9%)	(9.94-14.8%)	(9.7-15.8%)

Five-year relative survival by diagnosis year and age at diagnosis

	Five-year relative survival (with 95% confidence interval) by diagnosis year				EUROCARE-4	EUROCARE-4
Age at diagnosis	1994-97	1998-2002	2003-2007	2007-2009	##1995-1999	##1995-1999
	cohort	cohort	cohort	*hybrid	Ireland	Europe average

all 15-99	5.5%	5.8%	6.2%	6.2%
(unstandardized)	(4.2-7.1%)	(4.5-7.1%)	(4.7-8.1%)	(4.7-8.1%)

all 15-99	5.7%	6.5%	7.3%	8.1%	6.7%	5.7%
(age-standardized)#	(2.9-10.1%)	(3.8-10.2%)	(4.0-11.8%)	(4.5-12.9%)	(5.2-8.6%)	(5.4-6.0%)

15-44	13.1%	27.2%	33.6%	44.2%
	(3.3-29.8%)	(15.6-40.1%)	(20.5-47.2%)	(25.5-61.3%)

45-54	7.3%	6.3%	5.3%	4.3%
	(3.2-13.7%)	(2.8-11.9%)	(1.6-12.2%)	(1.1-11.5%)

55-64	3.8%	4.7%	4.1%	3.3%
	(1.7-7.3%)	(2.6-7.8%)	(2.0-7.3%)	(1.5-6.4%)

65-74	5.1%	4.8%	6.5%	6.5%
	(3.1-7.8%)	(3.0-7.0%)	(3.9-10.0%)	(3.9-10.1%)

75-99	5.4%	4.6%	5.1%	6.2%
	(3.3-8.3%)	(2.9-7.0%)	(2.7-8.6%)	(3.7-9.7%)

Footnotes:

*Hybrid estimate for 2007-2009 is the most up-to-date survival estimate and is based on follow-up of all cases alive at any point during this period,

supplemented by follow-up 2005-2009 for cases diagnosed in 2005 or 2006 (to provide more reliable estimation of the first two years of survival).

In practice, the hybrid estimate for 2007-2009 is similar to the most recent (incomplete) cohort, i.e. cases diagnosed 2003-2007, reflecting substantial overlap of data.

# Age-standardized figures use the standard patient population proposed for this cancer by:

Corazziari I., Quinn M. & Capocaccia R. 2004. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 2307-2316.

(Population weights = age 15-44 x7000, 45-54 x12000, 55-64 x23000, 65-74 x29000, 75-99 x29000)

## For comparison, the age-standardized average survival is quoted for countries (including Ireland) that participated in the EUROCARE-4 study:

Sant M. et al. 2009. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 45: 931-991.

Exclusions (as in EUROCARE):

Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases; second or subsequent malignancies in the same patient

(or the less serious of two or more synchronously-diagnosed malignancies); in situ carcinomas and tumours of uncertain behaviour.